GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » YoY EPS Growth

OBI Pharma (ROCO:4174) YoY EPS Growth : 14.47% (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. OBI Pharma's YoY EPS Growth for the quarter that ended in Mar. 2025 was 14.47%.

OBI Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was NT$-1.95.


OBI Pharma YoY EPS Growth Historical Data

The historical data trend for OBI Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma YoY EPS Growth Chart

OBI Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.56 -5.88 5.52 36.76 -116.41

OBI Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.21 -231.87 8.44 -31.61 14.47

OBI Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

OBI Pharma's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-9.89--4.57)/ | -4.57 |
=-116.41 %

OBI Pharma's YoY EPS Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EPS Growth (Q: Mar. 2025 )
=(Earnings per Share (Diluted) (Q: Mar. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(-1.95--2.28)/ | -2.28 |
=14.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OBI Pharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of OBI Pharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma Business Description

Traded in Other Exchanges
N/A
Address
No. 508, Section. 7, Zhongxiao East Road, 6th Floor, Nangang District, Taipei, TWN, 115011
OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.

OBI Pharma Headlines

No Headlines